In Q1 2026, Molina Healthcare experienced a 4% decline in premium revenue driven by Medicaid membership decreases resulting from market contraction and contract expirations. The company recorded a $93 million impairment related to its planned exit from the Medicare Advantage Prescription Drug (MAPD) product line in 2027, signaling a strategic refocus on dual-eligible members. Rising medical care ratios across Medicaid and Medicare segments pressure margins amid utilization cost growth. Molina's competitive moat rests on regulatory barriers and scale across 21 states serving around 5 million members, but evolving enrollment dynamics and regulatory capital limits constrain near-term expansion. Key milestones include monitoring membership trends, medical loss ratio trajectories, and execution of pricing and market exits.